This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Future oncology (London, England) · 2025
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
European urology · 2025
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
The Lancet Oncology · 2023
Latest funding
- $1,575,898
Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial
CIHR · 2026 · Nominated PI
- $2,487,015
TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.
CIHR · 2024 · Co-investigator
- $1,602,675
Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative (Radio)Therapy: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
CIHR · 2023 · Nominated PI
13 publications.
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Conduit C, Inderjeeth AJ, Allen R, Martin AJ, Parulekar W, Mulroe E, McJannett M, Zielinski RR, Thomson A, Tan TH, Sandhu SK, Reaume MN, Pook DW, North SA, Marx GM, Joshua A, Horvath L, McDermott R, Chowdhury S, Chi KN, Zhang AY, Stockler MR, Davis ID, Sweeney CJ, ANZUP Cancer Trials Group
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
Ravi P, Xie W, Buyse M, Halabi S, Kantoff PW, Sartor O, Attard G, Clarke N, D'Amico A, Dignam J, James N, Fizazi K, Gillessen S, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, N K, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM
Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial.
Petersen PM, Cook AD, Sydes MR, Clarke N, Cross W, Kynaston H, Logue J, Neville P, Patient Representative, Payne H, Parmar MKB, Parulekar W, Persad R, Saad F, Stirling A, Parker CC, Catton C
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32
Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, Hershman DL, Whelan T, Stambolic V, Mayer I
Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.
Ethier JL, Anderson GM, Austin PC, Clemons M, Parulekar W, Shepherd L, Summers Trasiewicz L, Tu D, Amir E
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Davis ID, ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, Cross W, Logue J, Parulekar W, Payne H, Persad R, Pickering H, Saad F, Anderson J, Bahl A, Bottomley D, Brasso K, Chahal R, Cooke PW, Eddy B, Gibbs S, Goh C, Gujral S, Heath C, Henderson A, Jaganathan R, Jakobsen H, James ND, Kanaga Sundaram S, Lees K, Lester J, Lindberg H, Money-Kyrle J, Morris S, O'Sullivan J, Ostler P, Owen L, Patel P, Pope A, Popert R, Raman R, Røder MA, Sayers I, Simms M, Wilson J, Zarkar A, Parmar MKB, Sydes MR
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Berry D, Clarke N, Collette L, D'Amico A, Lourenco RA, Dignam J, Eisenberger M, James N, Fizazi K, Gillessen S, Loriot Y, Mottet N, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ, ICECaP Working Group
Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial
Principal investigators: Parulekar, Wendy R; Ethier, Josee-Lyne
Keywords: Endocrine Therapy; Endometrial Cancer; International; Molecular Classification; Non-Inferiority; Phase Iii; Quality Of Life; Radiotherapy; Randomized
TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.
Principal investigators: Ong, Michael; Jafri, mariam
Keywords: Androgen Deprivation Treatment (Adt); Androgen Receptor Pathway Inhibitors (Arpi); Circulating Tumour Dna (Ctdna); Docetaxel; International; Metastatic Castration-Sensitive Prostate Cancer; Prostate Specific Antigen (Psa); Randomized Controlled Trial
Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative (Radio)Therapy: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
Principal investigators: Parulekar, Wendy R; Poon, Ian
Keywords: Head And Neck Cancer; Quality Of Life; Radiation Therapy; Randomized Phase Iii Trial; Stereotactic Body Radiation Therapy (Sbrt)
oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes
Principal investigators: Kolinsky, Michael; Jafri, mariam
Keywords: Dna Damage Response (Ddr) Genes; Economics; Genomic Testing; Metastatic Castration-Resistant Prostate Cancer; Patient-Reported Outcomes; Personalized Medicine; Platinum Chemotherapy; Quality Of Life; Randomized Controlled Trial
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial
Principal investigators: Parulekar, Wendy R; Welch, Stephen A
Keywords: Adjuvant Therapy; Endometrial Cancer; Immunotherapy; Mismatch Repair Deficiency; Molecular Classification; Personalized Medicine; Predictive Biomarkers; Quality Of Life; Randomized Phase Iii Trial
Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)
Principal investigators: Loblaw, Douglas Andrew B
Keywords: Progression-Free Survival; Prostate Cancer; Radiotherapy; Randomized Controlled Trial; Tolerability
SPECT-CT Guided ELEctive Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial
Principal investigators: Parulekar, Wendy R; de Almeida, John R; Hosni Abdalaty, Ali
Keywords: Cost Utility; De-Intestification; Image-Guided Treatment; Lymphatic Mapping; Oropharyngeal Cancer; Quality Of Life; Spect-Ct; Volume De-Intesification
A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
Principal investigators: Parulekar, Wendy R; Bratman, Scott V
Keywords: Cooperative Group; De-Escalation; Head And Neck Cancer; Human Papillomavirus; Multi-Institutional; Oropharynx Cancer; Phase Ii Clinical Study; Radiotherapy
A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
Principal investigators: Parulekar, Wendy R; Bratman, Scott V
Keywords: Cooperative Group; De-Escalation; Head And Neck Cancer; Human Papillomavirus; Multi-Institutional; Oropharynx Cancer; Phase Ii Clinical Study; Radiotherapy
A Randomized Trial of Regional Radiotherapy in Luminal A Breast Cancer
Principal investigators: Whelan, Timothy J
Keywords: Biomarkers; Breast Cancer; Radiation Therapy
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Mark Clemons and Eitan Amir: 13 shared papers
- Timothy Whelan and Vuk Stambolic: 10 shared papers
- Eitan Amir and Philippe Bedard: 4 shared papers
- Josee-Lyne Ethier and Eitan Amir: 3 shared papers
- Vuk Stambolic and Eitan Amir: 2 shared papers
- Eitan Amir and Steven Gallinger: 2 shared papers
- Sebastien Hotte and Wendy Parulekar: 1 shared paper
- Timothy Whelan and Wendy Parulekar: 1 shared paper
- Timothy Whelan and Steven Gallinger: 1 shared paper
- Timothy Whelan and Philippe Bedard: 1 shared paper
- Mark Clemons and Wendy Parulekar: 1 shared paper
- Mark Clemons and Josee-Lyne Ethier: 1 shared paper
- Mark Clemons and Philippe Bedard: 1 shared paper
- Vuk Stambolic and Wendy Parulekar: 1 shared paper
- Wendy Parulekar and Josee-Lyne Ethier: 1 shared paper
- Wendy Parulekar and Eitan Amir: 1 shared paper
- Wendy Parulekar and Steven Gallinger: 1 shared paper
- Wendy Parulekar and Philippe Bedard: 1 shared paper
- Department of Medicine
- Oncology
- Cancer Care and Epidemiology
- Clinical Epidemiology
- Medical Biophysics
- Research
- Other
Co-authors at Queen's University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Josee-Lyne Ethier
Cancer Care and Epidemiology
1 shared papers, latest 2021
Eitan Amir
Department of Medicine
1 shared papers, latest 2021
Steven Gallinger
Medical Biophysics
1 shared papers, latest 2023
Philippe Bedard
Department of Medicine
1 shared papers, latest 2021
Sebastien Hotte
Oncology
1 shared papers, latest 2023
Timothy Whelan
Oncology
1 shared papers, latest 2021
Mark Clemons
Clinical Epidemiology
1 shared papers, latest 2021
Vuk Stambolic
Research
1 shared papers, latest 2021
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.